The Penn State Cancer Institute is a cancer research center of the Penn State Milton S. Hershey Medical Center located in Hershey, Pennsylvania. The Institute provides clinical care, research, education, and community outreach services throughout central and eastern Pennsylvania.

During the past decade, Penn State Hershey Cancer Institute-Clinical Trials Office conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Penn State Hershey Cancer Institute-Clinical Trials Office" #1 collaborator was "Breast International Group" with 1 trials as a collaborator, "Cancer and Leukemia Group B" with 1 trials as a collaborator, "NCIC Clinical Trials Group" with 1 trials as a collaborator, "NSABP Foundation Inc" with 1 trials as a collaborator and "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Penn State Hershey Cancer Institute-Clinical Trials Office" are "AML" (1 trials), "Adult Hepatocellular Carcinoma" (1 trials), "Advanced Adult Hepatocellular Carcinoma" (1 trials), "Estrogen Receptor Positive Breast Cancer" (1 trials) and "Localized Non-Resectable Adult Liver Carcinoma" (1 trials). Many other conditions were trialed in "Penn State Hershey Cancer Institute-Clinical Trials Office" in a lesser frequency.

Most popular intervention types in "Penn State Hershey Cancer Institute-Clinical Trials Office" are "Drug" (4 trials), "Other" (2 trials), "Biological" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (2 trials), "CUDC-907" (1 trials), "Cixutumumab" (1 trials), "Exemestane" (1 trials) and "Obatoclax" (1 trials). Other intervention names were less common.

The vast majority of trials in "Penn State Hershey Cancer Institute-Clinical Trials Office" are 3 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Penn State Hershey Cancer Institute-Clinical Trials Office". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Penn State Hershey Cancer Institute-Clinical Trials Office, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Penn State Hershey Cancer Institute-Clinical Trials Office, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".